3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Pancreatic Neoplasms
4
Ovarian Neoplasms
2
Colorectal Neoplasms
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Neoplasms
1
Metastatic Pancreatic Adenocarcinoma
1
Metastatic Adenocarcinoma of the Pancreas
1
Locally Advanced Pancreatic Carcinoma(LAPC)
1
Head and Neck Neoplasms
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Biliary Tract Neoplasms
1
Advanced Pancreatic Cancer
1
Interventions
Carboplatin
42
Etoposide
37
Cisplatin
23
Topotecan
22
Nivolumab
17
pembrolizumab
12
atezolizumab
12
Ipilimumab
10
Paclitaxel
9
durvalumab
8
Irinotecan
8
Radiosurgery
6
Pemetrexed
6
rovalpituzumab tesirine
5
Magnetic Resonance Spectroscopy
5
trioctyl phosphine oxide
4
trilaciclib
4
etoposide phosphate
4
berzosertib
4
Sunitinib
4
Specimen Handling
4
Platinum
4
PM 01183
4
Dexamethasone
4
veliparib
3
tremelimumab
3
olaparib
3
carfilzomib
3
cabozantinib
3
Temozolomide
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Small Cell Lung Carcinoma
×
irinotecan sucrosofate
×
Clear all
NCT03088813
2025-02-19
RESILIENT
Ipsen
Phase 3
Completed
491 enrolled
24 charts